Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy f – PharmiWeb.com

DGAP-News: Evotec SE / Key word(s): Miscellaneous04.02.2021 / 07:30 The issuer is solely responsible for the content of this announcement. Hamburg, Germany, 04 February, 2021:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf ("UKE") for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure. Under the terms of the partnership, Evotec and UKE will leverage their complementary strengths for the development of a new cell therapy approach using Engineered Heart Tissue for the treatment of heart failure.

Read more
Global Adult Stem Cells Market Revenue To Witness Humongous Elevation By 2026 Market Research Store Jumbo News – Jumbo News

Global Adult Stem Cells Market Witnesses Significant Growth Amid The Latest COVID-19 Pandemic Crisis The globalAdult Stem Cells marketstudy maps the growth trajectory of the global Adult Stem Cells market by accurately evaluating all the vital factors that have a positive impact on the market growth. The Adult Stem Cells market report is expected to attain an accelerated growth and attain future prospects through the assessment of various facets of the Adult Stem Cells market. According to the report published by theMarket Research Store, the Adult Stem Cells market is predicted to attain vigorous momentum in its growth during the forecast owing to the increasing consumer base and market profiting growth stimulators.

Read more
New Research Study Investigates Metformin as a Therapy to Promote Brain Repair and Reduce Disability in Children and Young Adults with MS -…

TORONTO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Today the Multiple Sclerosis Society of Canada announced $400,000 in funding to support a pilot clinical trial to investigate the use of metformin as a therapy for children and young adults with multiple sclerosis (MS). In partnership with Stem Cell Network (SCN) and Ontario Institute for Regenerative Medicine (OIRM), this investment increases the funding for the trial to $1 million

Read more
[Full text] Retrospective Study on Implantation of Autologous-Cultured Osteoblasts | ORR – Dove Medical Press

Introduction Osteonecrosis of the femoral head is a progressive disorder that causes pain and often progresses to hip joint collapse, finally resulting in disabling arthritis.1,2 It occurs between 30 to 50 years of age, and prevails at a relatively younger age in Asians compared to their western counterparts.3 It is estimated that approximately 20,00030,000 new cases of osteonecrosis are diagnosed in the United States each year, accounting for 10% of total hip arthroplasties performed.4 The Indian Society of Hip and Knee Surgeons has reported that more than 50% of all hip replacements in India are performed for osteonecrosis.5 Many studies have reported osteonecrosis to be more prevalent in men compared to women (3 or 5:1).3 The underlying pathophysiology of osteonecrosis remains unclear; however, it is multifactorial and several traumatic and nontraumatic etiological factors may contribute to its development. Traumatic events that may cause osteonecrosis include femoral neck/head fracture, hip dislocation, or slipped capital femoral epiphysis

Read more
Adult Stem Cells Market Report By COVID-19 Outbreak- Business Growth Module, Threats, Opportunities and Competitive Landscape in 2021 Murphy’s Hockey…

Global Adult Stem Cells Report states the reshaping megatrends from 2015-2026 on regional as well as country level. The pandemic impact on different economies, changing business policies, Adult Stem Cells dynamics, and operations are evaluated in this report. The complete market performance during past, present, and forecast, Adult Stem Cells business strategies, developments, and SWOT analysis are presented

Read more